Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

Ascelia Pharma - Podcast with Deputy CEO Julie Waras Brogren and CSO Andreas Norlin

By Claus ThestrupCEO, Sweden
Ascelia Pharma

We have sat down with Ascelia Pharma Deputy CEO Julie Waras Brogren and CSO Andreas Norlin. In this podcast, we are covering the following topics:

Warrant TO1 - Exercise period ongoing:  Subscription period, price, and price calculation. What are gross proceeds at 100% participation?

Feedback from presenting Orviglance abstracts at scientific conferences: RSNA, Society of Abdominal Radiology Congress, ESGAR, ISPOR. What kind of feedback do you receive from the scientific community ie. clinicians, physicians, and KOL?  Do payers, policymakers, healthcare providers, patient organizations, and industry players participate?

Discussions with the FDA: Ascelia Pharma received a positive outcome from the FDA and are ready to file their NDA in mid-2025. What is the format when you discuss with the FDA?

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharam for a Corporate Visibility/Digital IR subscription agreement. /Claus Thestrup, 11.24 AM, 11 April 2025.

Recent videos

Talenom - Planned demerger and strategies of Talenom and Easor
2025-12-18 11:00 Talenom
Conference call with Fabege´s new CEO Bent Oustad
2025-12-18 10:00 Fabege
Investing in the life science sector
2025-12-18 07:47
Life Science Companies as Investments | Life Science Night Dec. 9, 2025
2025-12-16 08:30 Aiforia Technologies
Truecaller, Webcast, Press Conference, 2025
2025-12-15 13:00 Truecaller
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.